IngredientsPhosphatidylcholines (PC) are a class of glycerophospholipids that incorporate choline within the headgroup. PC is a basic component of cell membrane bilayers and the main phospholipid circulating in the plasma of blood; it has a phospholipid structure with a choline head group and a glycerophosphoric acid tail group. The tail group can be saturated or unsaturated, and more than one tail group may be present, with the tail groups being the same or different.
Phosphatidylcholines are such a major component of lecithin that in some contexts the terms are used as synonyms; however, lecithin extracts consist of a mixture of phosphatidylcholine and other compounds. The three main phospholipids in commercial soy lecithin are phosphatidylcholine (also called "pure" or "chemical" lecithin), phosphatidylethanolamine (popularly called "cephalin"), and phosphatidylinositols (also called inositol phosphatides).
Phosphatidylcholine is the most abundant phospholipid in eukaryotic cell membranes, generally constituting approximately 40–50% of total cellular phospholipids. It is a major constituent of cell membranes and pulmonary surfactant, and is more commonly found in the exoplasmic or outer leaflet of a cell membrane. Dipalmitoylphosphatidylcholine is a major component of the pulmonary surfactant, and is often used in the lecithin–sphingomyelin ratio to calculate fetal lung maturity.
While phosphatidylcholines are found in all plant and animal cells, they are absent in the membranes of most bacteria, including Escherichia coli.
Phosphatidylcholines are a major component of biological membranes and can easily be obtained from sources such as egg yolk or soybeans, from which they are mechanically or chemically extracted using hexane. They are a member of the lecithin group of yellow-brownish fatty substances occurring in animal and plant tissues.
Lecithin is found in many animal and vegetable sources, including beef liver, steak, eggs, peanuts, cauliflower, and oranges. Commercial lecithin products may be derived from plant sources (e.g., soybeans, sunflower seeds) and animal sources (e.g., egg yolk, bovine brain). Some commercial lecithin and lecithin supplements contain between 10% and 35% phosphatidylcholine.
The molecular species of PC vary substantially by source. Soy PC is particularly rich in species containing essential fatty acids, such as (18:2−18:2)PC (34.0%), (16:0−18:2)PC (20.8%), and (18:1−18:2)PC (16.3%). PC from animal sources such as ox liver and egg yolk contained major molecular species such as (16:0−18:2)PC, (16:0−18:1)PC, (18:0−18:2)PC, and (18:0−18:1)PC. Marine source (krill oil) is particularly rich in (16:0−20:5)PC and (16:0−22:6)PC, and represents an interesting potential source for food supplementation.
Soybeans are by far the most important source of commercial lecithin, and lecithin is the most important by-product of the soy oil processing industry because of its many applications in foods and in nonfood industrial products. Because of EU requirements to declare additions of allergens in foods, in addition to regulations regarding genetically modified crops, a gradual shift to other sources of lecithin — such as sunflower lecithin — is taking place.
Phosphatidylcholine is commercially available in several forms. Standard oral forms include softgel capsules and liquid preparations derived from soy or sunflower lecithin, with the phosphatidylcholine content standardized to varying degrees. A key distinction exists between crude lecithin and highly purified or concentrated PC preparations. A clinically relevant formulation is polyenylphosphatidylcholine (PPC), which refers to PC enriched in polyunsaturated fatty acids, typically derived from soybean. Conventional soybean lecithin may be enriched with polyenylphosphatidylcholine by adding soybean extracts containing high levels of PPC, and this type is referred to as "polyenylphosphatidylcholine-enriched" phosphatidylcholine, even where the term encompasses lecithin obtained from natural sources exhibiting PPC levels higher than ordinary soybean varieties.
Modified-release (delayed-release or retarded-release) oral formulations have been developed specifically for gastrointestinal applications, with the aim of delivering PC to the colonic mucosa rather than the upper gastrointestinal tract. Injectable formulations of PC — typically combined with sodium deoxycholate — have been used in aesthetic medicine contexts. Intravenous phospholipid emulsions (used in clinical nutrition) also contain PC as a primary component.
Lecithin was first isolated in 1845 by the French chemist and pharmacist Théodore Gobley. In 1850, he named the phosphatidylcholine "lécithine." Gobley originally isolated lecithin from egg yolk and established the complete chemical formula of phosphatidylcholine in 1874.
The name lecithin was derived from the Greek lékithos ('egg yolk') by Theodore Nicolas Gobley, a French chemist and pharmacist of the mid-19th century, who applied it to the egg yolk phosphatidylcholine. Gobley eventually described lecithin from a chemical structural point of view in 1874.
The presence of phosphorus-containing lipids in animal tissues was probably first noted by Vauquelin in 1812, in the fat-like material of the brain. Subsequently, in 1846, Gobley reported that egg yolk contained a phosphorus-containing lipid that he called "lecithin," derived from the Greek word for egg yolk. Later, Diakonow concluded that choline and fatty acids were also components of the lecithin molecule. Remarkably, as early as 1874, Johann Ludwig Wilhelm Thudichum showed that the products of the complete hydrolysis of lecithin were phosphoric acid, glycerol, fatty acids, and an organic base containing a nitrogen atom. He coined the term "phosphatides" for this class of molecules (now known as the phosphoglycerolipids).
Lecithin was proposed for use in treating liver ailments, hypercholesterolemia, and neurologic diseases, as well as in the food processing industry. Lecithin is the popular and commercial name for a naturally occurring mixture of phospholipids (formerly called phosphatides), which varies in color from light tan to dark reddish brown and in consistency from a fluid to a plastic solid. Lecithin is required for proper biological function and is a common compound found in cells of all living organisms.
By the mid-20th century, commercial extraction of lecithin from soybean oil had become industrially established. Soybeans became by far the most important source of commercial lecithin, with lecithin being the most important by-product of the soy oil processing industry. The injectable use of PC for treating tissue lipid deposits and xanthelasma was first described in the latter half of the 20th century, and its application as a hepatoprotective agent was formalized in Europe under the name "essential phospholipids" (EPL), primarily as a prescription drug (under names such as Essentiale) in Germany and other European and Soviet-era countries for liver disease, where it has been in clinical use for several decades.
Each PC molecule is an amphiphilic glycerophospholipid comprising a glycerol backbone esterified at the sn-1 and sn-2 positions with fatty acid chains, and at the sn-3 position with a phosphocholine head group. Their nature as amphophilic molecules provides them with unique physicochemical properties. This amphiphilicity — with a hydrophilic phosphocholine head and hydrophobic acyl tails — is what underlies the self-assembly of PC molecules into the lipid bilayers that constitute biological membranes.
Although multiple pathways exist for biosynthesis, the predominant route in eukaryotes involves condensation between diacylglycerol (DAG) and cytidine 5'-diphosphocholine (CDP-choline, or citicoline). This is known as the CDP-choline or Kennedy pathway. Phosphatidylcholine and related choline phospholipids are biosynthesized in mammals in the final step of the CDP-choline pathway by the choline phosphotransferases choline phosphotransferase 1 (CPT1) and choline/ethanolamine phosphotransferase 1 (CEPT1). A secondary route — the PEMT (phosphatidylethanolamine N-methyltransferase) pathway — involves sequential methylation of phosphatidylethanolamine. Neurons can synthesize choline by S-adenosylmethionine (SAM)-dependent methylation of phosphatidylethanolamine followed by hydrolysis to phosphatidylcholine; accordingly, methionine (after conversion to SAM) and serine can be ultimate precursors of choline.
Cell Membrane Structural Integrity. Phospholipids function as the principal components of cell membranes, making them essential for all vital cell processes. As the predominant phospholipid, PC determines membrane fluidity, permeability, and the function of membrane-embedded proteins. Phosphatidylcholine may help slow or prevent age-related changes in cortical thickness by delivering two molecules that are critical for cortical integrity: choline and long-chain polyunsaturated fatty acids.
Choline Provision and Acetylcholine Synthesis. Choline is the precursor of acetylcholine and directly influences acetylcholine synthesis in brain tissue, as well as being a precursor for phosphatidylcholine itself, which is required for membrane synthesis and maintenance of synaptic function. Phosphatidylcholine increases serum choline levels more effectively than orally administered choline; it may accordingly accelerate acetylcholine (ACh) synthesis in the brain through enhanced availability of choline. Choline-containing phospholipids such as PC act through two separate mechanisms: the precursors are first used as a substrate for acetylcholine synthesis, which can improve cholinergic neurotransmission.
Hepatic Lipid Transport and Membrane Repair. PC is an essential component of very-low-density lipoprotein (VLDL) particles, which are required for hepatic export of triglycerides. In states of PC deficiency, VLDL secretion is impaired, contributing to hepatic fat accumulation. EPL/PPC preparations have been shown in in vitro and animal models to exert antioxidant, anti-inflammatory, and lipid-regulating effects. Their positive influence on the grade of liver steatosis was highlighted in several randomized clinical trials based on histology, CT, and ultrasound dynamic evaluation; in preclinical studies, EPLs have shown antioxidant, anti-inflammatory, and lipid-regulating effects.
Intestinal Mucosal Barrier Function. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis. PC is a critical hydrophobic component of the mucus layer lining the colonic epithelium, providing a protective barrier against bacterial penetration and luminal irritants. Phosphatidylcholine is a key component of the mucosal barrier; treatment with modified-release phosphatidylcholine aims to improve impaired barrier function.
Gut Microbiota Metabolism: TMAO Pathway. A mechanistic link exists between intestinal microbial metabolism of the choline moiety in dietary phosphatidylcholine and coronary artery disease through the production of a proatherosclerotic metabolite, trimethylamine-N-oxide (TMAO). Certain gut bacteria catabolize the choline head group of PC to trimethylamine (TMA), which is then oxidized in the liver by flavin-containing monooxygenases to TMAO. The role of the TMAO metabolite derived by gut flora activity allows perceiving a novel cardiovascular risk scenario, as TMAO is a strong predictor of this condition.
One-Carbon Methyl Group Donation. Choline functions as a component of lipids including phosphatidylcholine, sphingomyelin, and lipid mediators such as platelet-activating factor; and as a component of the neurotransmitter acetylcholine. Via its hydrolysis product choline, PC participates in methylation reactions through conversion to betaine, contributing to the regulation of homocysteine metabolism.
Signal Transduction. Phospholipase D catalyzes the hydrolysis of phosphatidylcholine to form phosphatidic acid (PA), releasing the soluble choline headgroup into the cytosol. Phosphatidic acid is itself a signaling lipid, and this enzymatic pathway participates in intracellular signal transduction cascades involved in proliferation, cytoskeletal reorganization, and membrane trafficking.
The most extensively studied therapeutic application of PC (as EPL/PPC preparations) is in liver disease, particularly nonalcoholic fatty liver disease (NAFLD) and related conditions.
Early Randomized Trial (NAFLD with Type 2 Diabetes): One of the first clinical trials to show that EPL leads to improvement in histological steatosis was a randomized, placebo-controlled, double-blind study from Poland by Gonciarz et al. in 29 patients with NAFLD with type 2 diabetes mellitus. EPLs, given at 600 mg three times per day for 6 months, were associated with marked histological improvement in 4/15 (26.7%) patients in the EPL group versus 1/14 (7.1%) in the placebo group.
MANPOWER Study (Real-World, Russia): At baseline, the most frequently identified abnormalities on ultrasound were liver hyperechogenicity (84.0% of patients) and heterogeneous liver structure (62.9%). At 24 weeks, a significant improvement (p<0.05) in liver echogenicity and structure was observed in 1,932/2,827 (68.3%) and 1,207/2,827 (42.7%) patients, respectively. The study concluded that PPC adjunctive therapy may be useful in improving the ultrasonographic features of NAFLD in patients with associated cardiometabolic comorbidities.
Russian Real-Life Observational Study: In one study conducted in 28 patients with NAFLD with type 2 diabetes who received 2.1 g/day of PPC as adjuvant treatment, a significant reduction in liver function tests was observed. ALT, AST, and GGT levels decreased by a mean of 17.4, 10.4, and 9.1 U/L after 6 months, and this decrease was observed from the beginning of PPC therapy (p<0.05 compared with baseline at months 2, 4, and 6). Adjuvant treatment with PPC resulted in consistent improvements in liver enzymes in patients with newly diagnosed NAFLD and associated metabolic comorbidities.
China Real-World Study (MAFLD): Clinical evidence supporting the role of PPC in delaying liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) is limited. A multicenter, retrospective observational study evaluated the effectiveness of PPC in patients with MAFLD in China, including patients with type 2 diabetes or ≥2 metabolic dysregulations, divided into groups receiving either PPC or no hepatoprotective treatment.
Strength of evidence (liver): Mostly observational studies and open-label or small randomized trials with methodological limitations. Evidence is supportive but not yet definitive due to the predominance of unblinded designs, industry involvement in some studies, and the absence of large, rigorous placebo-controlled RCTs with hard histological endpoints. The evidence is classified as preliminary to moderate in strength.
The role of colonic mucosal PC deficiency in ulcerative colitis (UC) has been the focus of a focused clinical research program, primarily by researchers at Heidelberg, Germany.
Phase IIA RCT (Chronic Active UC): A phase IIA, double-blind, randomized, placebo-controlled study was performed in 60 patients with chronic active, non-steroid-dependent ulcerative colitis with a clinical activity index (CAI) ≥4. Retarded-release phosphatidylcholine-rich phospholipids and placebo were administered at a dose of 6 g daily over three months. The primary endpoint was a change in CAI towards clinical remission (CAI ≤3) or CAI improvement ≥50%. Secondary endpoints included ≥50% changes in endoscopic activity index, histology, and quality of life scores. Induction of clinical remission was attained by 16 (53%) patients in the phosphatidylcholine-treated group compared with three (10%) in the placebo group (p<0.00001).
Steroid-Refractory UC Trial (Annals of Internal Medicine): A randomized, double-blind, placebo-controlled trial enrolled 60 patients with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity indexes (score ≥5). Phosphatidylcholine or cellulose placebo was ingested 4 times daily for 12 weeks for a total dosage of 2 g/d.
Dose-Finding Study: Remission (CAI ≤3) was reached in 5/10 and 6/10 patients in the 3 g and 4 g dose groups, respectively, compared with no patients in the 0.5 g arm (p=0.033). In the 1 g dose group, only 3/10 patients reached remission. The rates of clinical response (≥50% CAI improvement) were 70% in all effective dose groups (1 to 4 g, p=0.003). A saturable dose response of delayed-release PC was found in the treatment of chronic-active ulcerative colitis, with effective doses ≥1 g per day; doses of 3 and 4 g appear superior in achieving remission.
Multicenter Phase 3 Trial (LT-02): A total of 156 patients with an inadequate response to mesalazine, a disease activity score (SCCAI) ≥5, and bloody diarrhea underwent treatment with 0, 0.8, 1.6, or 3.2 g LT-02. Subsequently, two larger phase 3 trials were conducted. Phosphatidylcholine is an essential constituent of the intestinal mucus previously shown to be beneficial in phase 2 studies; however, oral LT-02 plus mesalamine was not superior to placebo in inducing or maintaining remission. LT-02 was safe and well-tolerated. Despite prior evidence of beneficial effects of PC in phase 2 trials, the induction study with LT-02 in patients with mild to moderate UC was terminated prematurely for futility; signals of efficacy in maintenance therapy require confirmation in an adequately powered maintenance trial.
Strength of evidence (ulcerative colitis): Early phase 2 trials showed promising results. The subsequent phase 3 trials (LT-02/PCG-2 and PCG-4) did not confirm these findings for induction of remission in mild-to-moderate UC with mesalamine. Evidence is currently mixed, and the overall clinical evidence base is insufficient to support routine use. The modified-release formulation's delivery characteristics appear important to efficacy, and results across formulations cannot be generalized.
In addition to its roles in maintaining the structure and function of cell membranes, phosphatidylcholine acts as a source of the essential nutrient choline, which is important for the production of a brain chemical involved in learning and memory, called acetylcholine.
Observational Data: An analysis between nutrient intake and dementia risk in 3,224 participants from the Framingham Heart Study found that low dietary choline intake and low phosphatidylcholine intake were associated with higher dementia risk. A separate study including 2,497 Finnish men found that individuals with the highest dietary intake levels of phosphatidylcholine (>222 mg/day) had a 28% lower risk of dementia relative to those with the lowest intake (<144 mg/day). High phosphatidylcholine intake was also associated with better cognitive function.
Supplementation Trials: Large doses of lecithin (phosphatidylcholine) have been used to treat patients with dementia due to Alzheimer's disease in hopes of raising the amount of acetylcholine available in the brain; however, a systematic review of randomized controlled trials did not find lecithin to be more beneficial than placebo in the treatment of patients with cognitive impairment, vascular dementia, Alzheimer's disease, or mixed dementia.
The role of PC in cognitive impairment and dementias has been the focus of a Cochrane review (2003). No trials reported any clear clinical benefit of phosphatidylcholine for Alzheimer's disease or Parkinson's dementia. Only scarce clinical trials have led to data suitable for meta-analyses.
A 2009 systematic review of clinical trials in humans found insufficient evidence to support supplementation of lecithin or phosphatidylcholine in dementia, while noting that a moderate benefit could not be ruled out without further large-scale studies.
Phosphatidylcholine was the first cholinergic precursor molecule used, but it did not demonstrate clear clinical benefits. The same is not true for other phospholipids — CDP-choline and α-GPC — involved in choline biosynthetic pathways, for which an uncertain improvement of cognitive dysfunction in neurodegenerative and vascular dementia is documented. Positive results obtained with selected cholinergic precursors cannot be generalized due to the small numbers of patients studied in appropriate clinical trials.
Executive Function in Older Adults: The underlying physiological mechanisms of the relationship between phosphatidylcholine levels, cognitive flexibility, and cortical integrity of the inferior prefrontal cortex may be threefold: PC may help slow or prevent age-related changes in cortical thickness by delivering choline and long-chain polyunsaturated fatty acids; the delivery of long-chain polyunsaturated fatty acids may help prevent brain inflammation; and delivery of choline contributes to acetylcholine synthesis, a neurotransmitter implicated in set-shifting performance.
Strength of evidence (cognition): Observational studies show consistent associations between dietary PC intake and cognitive outcomes. Controlled supplementation trials of PC specifically have consistently failed to show cognitive benefit in clinical populations with dementia. Evidence is weak for therapeutic supplementation in established cognitive disease; observational evidence supports adequate dietary intake as potentially protective.
Choline is essential for fetal brain development, and it is not known whether a typical American diet contains enough choline to ensure optimal brain development. A study was undertaken to determine whether supplementing pregnant women with phosphatidylcholine (the main dietary source of choline) improves the cognitive abilities of their offspring.
In a double-blind, randomized controlled trial, 140 pregnant women were randomly assigned to receive supplemental phosphatidylcholine (750 mg) or a placebo (corn oil) from 18 weeks gestation through 90 days postpartum. Their infants (n=99) were tested for short-term visuospatial memory, long-term episodic memory, language development, and global development at 10 and 12 months of age. The intervention had no significant effect on neurocognition of the child at the age of 10 months. At 12 months, the long-term episodic memory task tended to be lower in the choline compared with the placebo group. The intervention had no significant effects on the composite index of global development, number of words spoken, short-term visuospatial memory, or long-term episodic memory.
Recent interest in choline has focused on its role in neural development, with compelling evidence in rodents that maternal dietary choline deficiency in pregnancy alters fetal brain development, with effects including decreased neural progenitor cell proliferation, increased apoptosis, and global histone, DNA, and gene-specific hypomethylation, culminating in lifelong alterations in cognitive and memory functioning.
Limited choline intake during pregnancy and lactation increases the susceptibility of the mother to develop choline deficiency. The prenatal and early postnatal periods are both critical developmental periods, regarded as being "sensitive windows of development," including to choline insufficiency.
Strength of evidence (pregnancy/fetal development): Rodent data are compelling and mechanistically well-characterized. Human supplementation trials with PC in pregnancy are limited; the one published RCT did not demonstrate significant cognitive benefit in offspring. Observational data linking dietary choline and PC intake to developmental outcomes are suggestive but subject to confounding.
The relationship between PC, its metabolites, and cardiovascular health is complex and involves both potentially beneficial and potentially harmful mechanisms.
TMAO and Cardiovascular Risk: The production of TMAO from dietary phosphatidylcholine is dependent on metabolism by the intestinal microbiota. Increased TMAO levels are associated with an increased risk of incident major adverse cardiovascular events. Increased plasma levels of TMAO were associated with an increased risk of a major adverse cardiovascular event (hazard ratio for highest vs. lowest TMAO quartile, 2.54; 95% confidence interval, 1.96 to 3.28; P<0.001). An elevated TMAO level predicted an increased risk of major adverse cardiovascular events after adjustment for traditional risk factors.
A high intake of phosphatidylcholine, which could lead to higher production of TMAO, was significantly associated with an increased risk of all-cause and CVD-specific mortality, particularly among diabetic patients.
Importantly, the TMAO risk appears to be microbiome-dependent and may vary by formulation. One study in non-pregnant, non-lactating people suggested that consuming choline from a choline bitartrate supplement increased TMAO concentrations; however, consuming an equivalent amount of choline from either phosphatidylcholine supplements or increased egg intake showed no significant increase in TMAO. These findings indicate that the form of choline ingested may affect the cardiovascular implications of choline supplementation.
Strength of evidence (cardiovascular/TMAO): The TMAO–cardiovascular risk association is robust in observational cohort studies and corroborated by mechanistic evidence, but causality has not been established by interventional trials. The differential effect by choline form adds complexity that requires further study.
Injection lipolysis or "mesotherapy" involves introducing various substances into deeper layers of the skin with the aim to dissolve subcutaneous fat. PC combined with sodium deoxycholate has been widely used off-label for this purpose. Subcutaneously injecting PC to eliminate unwanted local accumulations of fat was first proposed by Maggiori, who treated xanthelasma by using tissue injections of PC.
Injections of PC-DC can effectively reduce abdominal fat volume and thickness, with no serious adverse effects in healthy adult women, as observed in a small randomized study. One retrospective case series encompassing 1,616 patients receiving a total of 15,122 treatments reported that relatively modest volumes of injections produced satisfactory and smooth results in 74.5 to 86.5% of patients in the two practices.
The mechanism of fat reduction in injection lipolysis has been debated. Recent reports have suggested that fat reduction by PC injection was the result of its tissue-toxic effect and adipocyte death, rather than lipase-associated lipolysis. Deoxycholate alone and PC-DC both produced dose-dependent cell death in 3T3-L1 adipocytes, whereas PC alone had no effect. Neither PC alone nor the PC-DC combination induced lipolysis in this in vitro model.
Though phosphatidylcholine has been studied as an alternative to liposuction, no peer-reviewed study has shown it to have comparable effects.
Strength of evidence (body contouring): Evidence is limited to small and largely uncontrolled studies, and the mechanism of action of the commercially used PC/deoxycholate combination is not firmly established. The FDA has not approved PC-based injection lipolysis formulations for this use in the United States.
The following dosages are reported directly from published clinical studies and should not be interpreted as recommendations.
Adverse effects are usually not associated with lecithin. However, there have been reports of anorexia, nausea, sweating, increased salivation, other gastrointestinal effects, and hepatitis. In the dose-finding UC trial, bloating was registered in 40% of patients irrespective of the treatment dose, and three of ten patients in the 4 g dose group reported nausea. Modified-release LT-02 was safe and well-tolerated in the large phase 3 trial.
Injection lipolysis with PC/deoxycholate causes tissue fibrosis and necrosis of adipose and vascular tissues in both rat and human subjects, making the long-term safety of PC/DC for nonsurgical treatment of subcutaneous fat deposits uncertain. The safety profile of chemicals used in injection lipolysis is poorly regulated and may cause side effects or long-term sequelae that can be disastrous for the patient. Minor and rare side effects from injection lipolysis have included pain, lightheadedness, tender nodules, pigmentation, and ulceration.
Animal studies have shown a mechanistic link between intestinal microbial metabolism of the choline moiety in dietary phosphatidylcholine and coronary artery disease through the production of a proatherosclerotic metabolite, trimethylamine-N-oxide (TMAO). The relationship between fasting plasma levels of TMAO and incident major adverse cardiovascular events was examined during 3 years of follow-up in 4,007 patients undergoing elective coronary angiography. This TMAO risk signal is microbiome-dependent and varies between individuals based on gut bacterial composition.
Soy-derived PC supplements carry relevant allergen labeling considerations, as soy is a recognized major allergen. Sunflower-derived and egg-derived alternatives exist for those avoiding soy. Because of EU requirements to declare additions of allergens in foods, in addition to regulations regarding genetically modified crops, a gradual shift to other sources of lecithin such as sunflower lecithin is taking place.
Contraindications have not been formally identified for oral lecithin/PC supplementation; information regarding safety and efficacy in pregnancy and lactation is limited; and formal drug interactions are not well documented in the literature. PC may theoretically potentiate anticholinergic drugs by enhancing cholinergic tone through the acetylcholine biosynthetic pathway, though clinical data on specific interactions are lacking. Acetylcholine precursors have been shown to prolong the favorable effects of acetylcholinesterase inhibitors on cognitive and behavioral improvements in patients with Alzheimer's disease and mild to moderate vascular dementia.
PC is involved in one-carbon metabolism and methyl group donation. Because PC (via its choline constituent) contributes to homocysteine remethylation, high intakes of PC could theoretically interact with folate and vitamin B12 pathways relevant to homocysteine metabolism. These interactions have not been thoroughly characterized in clinical studies specific to PC supplementation.
Health conditions that Phosphatidylcholine may help support.
PC has been studied in clinical settings involving post-viral brain fog. As a choline donor and structural membrane lipid, it supports neuronal membrane integrity and ACh synthesis. A multicenter trial investigated PC in post-COVID cognitive impairment with brain fog.
PC is required for VLDL assembly and biliary cholesterol secretion. PC-derived choline metabolized to betaine can lower homocysteine, while PC itself has modest, context-dependent effects on blood lipids. LCAT uses PC to esterify cholesterol on HDL, central to reverse cholesterol transport.
PC inhibits TNF-α-induced pro-inflammatory signaling in intestinal and immune cells, potentially by shifting TNF-α receptors into lipid rafts. PC also modulates macrophage polarization and gut microbiota in IBD models. Clinical evidence is primarily derived from the ulcerative colitis setting.
Phosphatidylcholine (PC) is a major structural component of neuronal cell membranes and a key choline source for acetylcholine synthesis—a neurotransmitter critically depleted in Alzheimer's disease. Observational studies link higher dietary PC intake to lower dementia risk, and elevated plasma PC species are associated with slower cognitive decline longitudinally. However, RCTs of PC supplementation in cognitively impaired populations have not demonstrated clear cognitive benefit, making the evidence strongest for dietary adequacy and biomarker associations rather than supplementation per se.
The colonic mucus layer is normally enriched in PC, and patients with ulcerative colitis show significantly depleted mucosal PC. Multiple RCTs demonstrate that delayed-release PC supplementation reduces disease activity, induces remission, and supports steroid withdrawal in active UC. This is one of the best-evidenced therapeutic applications of PC.
PC is a choline donor supporting acetylcholine synthesis, which underpins attention and sustained concentration. Cholinergic deficits are well documented in attention-related disorders and normal aging. Clinical evidence for PC specifically improving focus is indirect but mechanistically coherent.
Phosphatidylcholine (PC) is the primary phospholipid in bile essential for maintaining cholesterol in solution and preventing gallstone formation. Genetic defects in biliary PC secretion (ABCB4 mutations) cause a specific form of cholelithiasis (LPAC syndrome). Supplemental PC is mechanistically sound for gallstone prevention and post-cholecystectomy bile support.
Phosphatidylcholine (lecithin) is one of the three primary components of bile, and its concentration in bile directly determines cholesterol solubility—lower phosphatidylcholine increases lithogenic risk. A PubMed-indexed clinical study (PMID 937323) investigated treatment of gallstone patients with lecithin. Nutritional reviews (PMID 19803550) list soy lecithin among supplements that might help prevent gallstones, and it is a recognized component of bile chemistry relevant to stone formation.
PC levels in the hippocampus and plasma decline with age, contributing to cholinergic insufficiency and membrane deterioration. Dietary PC intake is associated with reduced dementia risk and better cognitive performance in aging cohorts. PC supports multiple aging-relevant processes including methylation, membrane integrity, and ACh synthesis.
PC is essential for membrane biosynthesis and tissue expansion during rapid growth phases including fetal development, infancy, and childhood. It is the predominant choline compound in amniotic fluid and neonatal circulation. Low PEMT enzyme activity in the neonatal liver underscores dependence on exogenous PC supply during early development.
PC metabolism via gut microbiota generates TMAO, a metabolite clinically associated with increased cardiovascular risk in large cohort studies. Conversely, PC supports HDL function via LCAT and homocysteine reduction via betaine. The cardiovascular relationship of PC is bidirectional and dose/context dependent.
PC provides choline, which is oxidized to betaine—a methyl donor that remethylates homocysteine to methionine. Controlled clinical studies show that PC supplementation significantly lowers fasting and post-methionine-load plasma homocysteine in healthy men. The PEMT pathway for endogenous PC synthesis is also a significant source of homocysteine.
PC modulates gut barrier function, macrophage polarization, and gut microbiota structure in IBD. The strongest clinical evidence is in ulcerative colitis; Crohn's disease evidence is more limited. PC has been studied as both a therapeutic agent and drug carrier in IBD.
PC is a structural component of intestinal epithelial cell membranes and a key constituent of the mucus barrier that limits intestinal permeability. Depletion of mucosal PC, as seen in UC, is mechanistically linked to increased barrier dysfunction. PC's role in gut barrier support has direct biological relevance to leaky gut.
PC provides choline for acetylcholine biosynthesis, a neurotransmitter directly involved in learning and attention. Observational data link higher dietary PC intake to better cognitive function. Preclinical evidence is robust; clinical evidence in humans is more limited but supportive.
Phosphatidylcholine (PC) is an essential phospholipid critical to hepatocyte membrane integrity and lipid export from the liver. Polyenylphosphatidylcholine has been studied in alcoholic liver disease in a large VA multicenter RCT. A 2024 clinical trials review confirmed phospholipids reduce liver enzymes in clinical studies. Choline deficiency is established as a direct cause of hepatic steatosis.
Phosphatidylcholine (PC) is a direct precursor of acetylcholine, the neurotransmitter central to memory formation. Higher dietary PC intake is associated with lower dementia risk in large observational cohorts. A placebo-controlled clinical trial demonstrated significant improvement in explicit memory with acute PC supplementation. Clinical evidence is present but effect sizes in healthy adults are modest.
Metabolic syndrome is associated with impaired phospholipid metabolism, including altered phosphatidylcholine/lysophosphatidylcholine ratios linked to reduced LCAT activity and HDL dysfunction. PC is integral to VLDL assembly and hepatic lipid export, processes disrupted in metabolic syndrome. EPL/PC treatment improves liver enzyme profiles in NAFLD patients with metabolic comorbidities.
PC is synthesized de novo in the liver via the PEMT pathway, which requires three sequential methyl group transfers from S-adenosylmethionine. Conversely, choline from PC catabolism provides betaine, a methyl donor for homocysteine remethylation. PC thus sits at a critical intersection of the one-carbon metabolic network.
Phosphatidylcholine is a major structural phospholipid of neuronal cell membranes and a source of choline for acetylcholine synthesis. It supports neuronal membrane integrity, neurotransmitter production, and myelin synthesis, with evidence for cognitive support in aging and neurological conditions.
PC provides the choline substrate for ACh, which drives BDNF release and cholinergic neuron survival—key components of neuroplasticity. PC levels in the brain decline with aging, with consequences for neuronal structural integrity and adaptive capacity. Research links PC metabolism to the maintenance of basal forebrain cholinergic neurons.
PC is the direct biochemical precursor for acetylcholine synthesis. As a major dietary choline source, adequate PC intake is required to sustain cholinergic neurotransmission. Declining brain PC levels with aging correlate with reduced ACh availability and cognitive decline.
Phosphatidylcholine is the predominant phospholipid of cell membranes and the primary choline source for acetylcholine synthesis, supporting neurological function and liver health impaired in post-viral states. It is a key component of the phospholipid-based approaches to long COVID including LDN/LDH protocols. Liver membrane repair after COVID-19-induced hepatitis uses phosphatidylcholine.
PC is the primary dietary form of choline, an essential nutrient for fetal brain development, membrane biosynthesis, and epigenetic programming. Pregnancy dramatically increases demand for PC/choline for fetal tissue expansion and neurodevelopment. Maternal PC supplementation has been studied in RCTs for infant neurocognitive outcomes.
Body systems that Phosphatidylcholine may help support.
Go back